Advocacy Feature image
ePolicy 300x175
eAdvocacy Center 300x175
  • news-thumbnail

    Contact Congress to Support SGR Repeal

    March 26, 2015
    Urge the Senate to Pass SGR Repeal Legislation Immediately
    After nearly two decades, the time for permanent repeal of Medicare's Sustainable Growth Rate (SGR) is finally upon us! Read more
  • news-thumbnail

    ePolicy News March 2015

    March 12, 2015
    An Overview of the President’s FY 2016 Budget
    On Feb. 2, President Obama submitted the White House’s Fiscal Year (FY) 2016 budget to Congress. The Administration’s proposed $4 trillion budget would produce a $474 billion deficit (roughly 2.5 percent of the gross domestic product). If enacted, its policies would add approximately $5.7 trillion to the national debt over 10 years. When compared with the $8 trillion increase projected under current law, this represents a roughly 30-percent reduction in the growth in national debt by 2026. Finally, the President aimed to fully reverse the sequester by proposing to increase discretionary spending to $74 billion above the current mandatory spending caps. Read more
  • news-thumbnail

    ePolicy News February 2015

    February 03, 2015
    ASCP Announces New Choosing Wisely® Recommendations
    ASCP has released a new set of Choosing Wisely® recommendations targeting laboratory tests that are commonly ordered, but not always appropriate. ASCP has been a partner in the Choosing Wisely® campaign, an initiative of the American Board of Internal Medicine (ABIM) Foundation, since 2013 when the Society released its first set of Choosing Wisely® recommendations. Read more
  • news-thumbnail

    ePolicy News January 2015

    January 12, 2015
    FDA LDT Proposal Under the Microscope
    The controversy over the regulation of laboratory developed tests (LDTs) heated up this month in a public forum organized by the Food and Drug Administration (FDA) to discuss its proposal for a risk-based approach to regulate these assays. The Agency’s issuance last fall of a proposed framework for the regulation of LDTs signaled the end of the FDA's long-standing policy of "enforcement discretion." Read more